Immediate vs delayed azathioprine or rituximab for children with anti-MOG attacks
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 3 trial tests whether starting anti-inflammatory treatment right away is better than waiting, using either azathioprine or rituximab, for children with anti-MOG antibody–related acute demyelinating episodes. It may help reduce future attacks and disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is 6 to under 18 years old
- Child weighs at least 20 kg
- Anti-MOG antibodies are confirmed, and symptoms started more than 24 hours ago from an inflammation-related episode (such as optic neuritis, spinal cord inflammation, brainstem/rhombencephalitis, ADEM, or NMOSD)
- Child has not had any treatment for this episode yet, except steroids
- Child’s disability score (EDSS) is under 5.5 at screening, and blood tests (immune cells, platelets, hemoglobin, kidney and liver function) are above required minimums
- No certain ongoing problems: no active infections like COVID-19, TB, hepatitis B/C, or HIV; no prior serious allergy to azathioprine/rituximab; and no uncontrolled cancer or uncontrolled blood pressure/heart issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether azathioprine can help prevent problems after a first attack of MOG antibody–related inflammation of the brain/spinal cord. It’s for adults with a recent first episode and confirmed MOG antibodies.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This trial tests a new medicine called inectolizumab, combined with optimized steroid therapy, for people having their first attack of neuromyelitis optica spectrum disorder (NMOSD). The goal is to see if this combination better controls the disease and prevents future attacks.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
Hear when a new Acute Demyelinating Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.